Cercar
01/06/2024
Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC)
John, T, Grohe, C, Goldman, JW, Kato, T, Laktionov, KK, Bonanno, L, Tiseo, M, Majem, M, Domine, M, Ahn, MJ, Perol, M, Hartmaier, R, Robichaux, J, Bhetariya, P, Markovets, A, Rukazenkov, Y, Muldoon, C, Herbst, RS, Tsuboi, M, Wu, YL. Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).
01/06/2024
First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas
González-Lopez, JA, Sebio, A, Hindi, N, Jimenez, M, Villarejo-Campos, P, Martin-Broto, J, Díaz-Beveridge, R, Castellanos, JFO, Andújar, RL, Alvarez, RA, Asencio, JM, Serrano, C, Conde, NR, Boix, SC, Gimenez-Salinas, LK, Garcia, JAT, Campos, AP, Lopera, E, Bertran, J, Pousa, AL. First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).
01/06/2024
Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
Garassino, MC, Wakelee, HA, Spicer, J, Liberman, M, Kato, T, Tsuboi, M, Lee, SH, Chen, KN, Dooms, CA, Majem, M, Eigendorff, E, Martinengo, GL, Bylicki, O, Rodriguez-Abreu, D, Chaft, JE, Yang, J, Arunachalam, A, Norquist, JM, Keller, SM, Gao, SG. Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).
01/06/2024
Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase II NeoFox study
Soler, RS, Vivas, CS, Macias, I, Esteban, AY, Bassam, A, Plazas, JG, Al-Farhat, Y, Cervantes, A, Alfonso, PG, Paez, D, Ruiz-Casado, A, Lopez, C, Arkosy, PF, Furka, A, Rodriguez-Salas, N, Pascual, FJR, Gracian, AC, Hitre, E, Monteagudo, RF, Salvia, MAS. Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase II NeoFox study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.020. PMID:. IF:65.400(Q1/1D).
01/06/2024
Be aware of the X: BCOR mutations in myeloid neoplasms
Ramil, G, Pratcorona, M, Nomdedéu, JF. Be aware of the X: BCOR mutations in myeloid neoplasms. HAEMATOLOGICA. 2024; 109(6)DOI:10.3324/haematol.2023.284748. PMID:38328862. IF:10.100(Q1/2D).
01/06/2024
CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas
Virgili, AC, Salazar, J, Gallardo, A, López-Pousa, A, Terés, R, Bagué, S, Orellana, R, Fumagalli, C, Mangues, R, Alba-Castellón, L, Unzueta, U, Casanova, I, Sebio, A. CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas. Diagnostics. 2024; 14(11)DOI:10.3390/diagnostics14111195. PMID:38893721. IF:3.300(Q1/2D).